1. Home
  2. TMP vs REPL Comparison

TMP vs REPL Comparison

Compare TMP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tompkins Financial Corporation

TMP

Tompkins Financial Corporation

N/A

Current Price

$99.42

Market Cap

1.4B

Sector

Finance

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$21.71

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TMP
REPL
Founded
1836
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
TMP
REPL
Price
$99.42
$21.71
Analyst Decision
Hold
Buy
Analyst Count
2
8
Target Price
★ $105.50
$23.33
AVG Volume (30 Days)
89.9K
★ 2.9M
Earning Date
10-23-2026
10-28-2026
Dividend Yield
★ 2.80%
N/A
EPS Growth
★ 126.16
N/A
EPS
★ 5.86
N/A
Revenue
★ $75,742,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.47
$513.15
P/E Ratio
$17.50
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$64.16
$1.50
52 Week High
$105.00
$21.26

Technical Indicators

Market Signals
Indicator
TMP
REPL
Relative Strength Index (RSI) 49.75 79.20
Support Level $95.19 $6.82
Resistance Level $102.07 N/A
Average True Range (ATR) 2.72 1.36
MACD -0.07 0.90
Stochastic Oscillator 25.10 99.76

Price Performance

Historical Comparison
TMP
REPL

About TMP Tompkins Financial Corporation

Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: